Active Studies

RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to
help focus thin beams of radiation directly on the tumor, and giving radiation therapy in
higher doses over a shorter period of time, may kill more tumor cells and have fewer side
effects. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them. It is not yet known whether radiation
therapy is more effective when given alone or together with cetuximab in treating patients
with head and neck cancer that has been removed by surgery.

PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it
works compared with radiation therapy given together with cetuximab in treating patients who
have undergone surgery for locally advanced head and neck cancer.

The purpose of this study is to examine whether or not providing Chantix (varenicline) will
help African American smokers quit smoking.

The purpose of this study is to test the effectiveness of a culturally-tailored
Internet-based program that helps American Indian (AI) tribal college students quit smoking.

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or
exemestane, may fight breast cancer by lowering the amount of estrogen the body makes.
Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. It is not yet know whether hormone therapy is more effective when given with or
without everolimus in treating breast cancer.

PURPOSE: This randomized phase III trial studies how well giving hormone therapy together
with or without everolimus work in treating patients with breast cancer.

This screening and multi-sub-study randomized phase II/III trial will establish a method for
genomic screening of similar large cancer populations followed by assigning and accruing
simultaneously to a multi-sub-study "Master Protocol". The type of cancer trait (biomarker)
will determine to which sub-study, within this protocol, a participant will be assigned to
compare new targeted cancer therapy, designed to block the growth and spread of cancer, or
combinations to standard of care therapy with the ultimate goal of being able to approve new
targeted therapies in this setting. In addition, the protocol includes a "non-match"
sub-study which will include all screened patients not eligible for any of the
biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of
care also with the goal of approval.

Pages